Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AML

Relapsed Acute Myelogenous Leukemia Clinical Trial

Official title:

Open Label Dose Escalation Trial of an Adaptive Natural Killer (NK) Cell Infusion (FATE-NK100) With Subcutaneous IL-2 in Adults With Refractory or Relapsed Acute Myelogenous Leukemia (AML)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03081780
• Other study ID #: 2016LS153
• Status: Completed
• Phase: Phase 1
• Start date: April 27, 2017
• Est. completion date: December 1, 2020

Study information

• Verified date: March 2021
• Source: Masonic Cancer Center, University of Minnesota
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase I open-label dose escalation study of a single infusion of FATE-NK100 and a short course of subcutaneous interleukin-2 (IL-2) administered after lymphodepleting chemotherapy (CY/FLU) in subjects with refractory or relapsed acute myelogenous leukemia (AML). FATE-NK100 is a natural killer (NK) cell product that is enriched for NK cells with an "adaptive", or human cytomegalovirus (CMV)-induced, phenotype. The NK cell product is comprised of peripheral blood (PB) leukocytes sourced from a related donor (HLA-haploidentical or better but not fully HLA-matched) that is seropositive for cytomegalovirus (CMV+), and enriched for adaptive NK cells by depletion of CD3+ (T-lymphocytes) and CD19+ (B-lymphocytes) cells followed by ex-vivo culture expansion.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: December 1, 2020
• Est. primary completion date: August 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• =18 but = 70 years of age
• Diagnosis of acute myeloid leukemia (AML) and meets one of the following disease

criteria:

• Primary induction failure:

** De Novo AML: no CR after 2, 3 or 4 induction attempts with high dose chemotherapy

• Secondary AML (from MDS or treatment related): no CR after 1, 2 or 3 cycles of high dose chemotherapy
• Relapsed:
• Not in CR after 1 or 2 cycles of standard re-induction therapy
• Relapse diagnosed at the time of the 6 months post-HCT standard of care follow-up or later (i.e. based on bone marrow biopsy performed Day +170 or later) and without evidence of graft versus host disease (GVHD)
• For patients > 60 years of age, the minimum of 1 cycle of standard chemotherapy is not required.
• Available HLA-matched or better but not fully HLA-matched (2/4 or 3/4 antigens) related donor (aged 18 to 75 years) with donor/recipient match based on a minimum of intermediate resolution DNA based Class I typing of the A and B locus who is CMV seropositive.
• Karnofsky Performance Status = 60%
• Adequate organ function within 14 days of study registration (28 days for pulmonary

and cardiac) defined as:

• Creatinine: Estimated glomerular filtration rate (eGFR) = 50 mL/min/1.73m^2 per current institutional calculation formula
• Hepatic: AST and ALT = 3 x upper limit of institutional normal
• Pulmonary Function: oxygen saturation = 90% on room air; PFT's required only if symptomatic or prior known impairment - must have pulmonary function >50% corrected DLCO and FEV1
• Cardiac Function: LVEF = 40% by echocardiography or MUGA
• No symptomatic active conduction system abnormalities
• Able to be off prednisone or other immunosuppressive medications for at least 3 days prior to FATE-NK100 cell infusion (excluding preparative regimen premedications)
• Sexually active females of child bearing potential and males with partners of child bearing potential must agree to use effective contraception during therapy and for 4 months after completion of therapy
• Voluntary written consent prior to the performance of any research related procedures Arm Specific Inclusion Criteria

High-Risk aGVHD (ARM 1):

• Pediatric or adult (ages 0-76 years) HCT recipients with high-risk acute GVHD, as determined either by the refined MN acute GVHD risk score [28]: http://z.umn.edu/MNAcuteGVHDRiskScore OR high risk on the basis of blood biomarkers (Ann Arbor Score 3) [31]. Patients in this arm must start treatment within the first 7 days after onset of high-risk aGVHD. or

Steroid- Dependent aGVHD (ARM 2A):

• Pediatric or adult (ages 0-76 years) HCT recipient with grade II-IV steroid-dependent acute GVHD, defined as any one of the following: Flare of acute GVHD of at least grade II/IV severity within 8 weeks of tapering down or (off of) immunosuppression for acute GVHD, with the flare occurring on =0.5 mg/kg prednisone. This can include late-onset aGVHD and overlap syndrome. or

Steroid-Refractory aGVHD (ARM 2B):

• Pediatric or adult (ages 0-76 years) HCT recipient with grade II-IV steroid refractory

acute GVHD, defined as any one of the following:

• No response of acute GVHD after at least 4 days of systemic corticosteroids of at least 2 mg/kg prednisone or equivalent
• Progression of acute GVHD within 3 days of systemic corticosteroids of at least 2 mg/kg prednisone or equivalent
• Failure to improve to at least grade II acute GVHD after 14 days of systemic corticosteroids, with initial doses of at least 2 mg/kg prednisone or equivalent
• Flare of acute GVHD of at least grade II/IV severity while on steroids at a dose >0.5/mg/kg/day. This can include late-onset aGVHD and overlap syndrome.

Exclusion Criteria:

• Myocardial Infraction (MI) within the previous 6 months
• Acute leukemias of ambiguous lineage
• Pregnant or breastfeeding - The agents used in this study include those that fall under Pregnancy Category D - have known teratogenic potential. Women of child bearing potential must have a negative pregnancy test at screening
• History of or known active CNS involvement with AML
• Active autoimmune disease requiring systemic immunosuppressive therapy
• History of severe asthma and currently on chronic systemic medications (mild asthma requiring inhaled steroids only is eligible)
• New or progressive pulmonary infiltrates on screening chest X-ray or chest CT scan unless cleared for study by Pulmonary. Infiltrates attributed to infection must be stable/improving (with associated clinical improvement) after 1 week of appropriate therapy (4 weeks for presumed or documented fungal infections).
• Uncontrolled bacterial, fungal or viral infections including HIV-1/2 or active hepatitis C/B - chronic asymptomatic viral hepatitis is allowed
• Received any investigational agent within the 14 days before the start of study treatment (1st dose of fludarabine)

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Refractory Acute Myelogenous Leukemia
• Relapsed Acute Myelogenous Leukemia

Intervention

Biological:
• FATE-NK100
Preparative regimen: Fludarabine 25 mg/m2 x 5 days start Day -6 Cyclophosphamide 60 mg/kg x 2 days on Day -5 and -4 Apheresis cell collection (collected from the Donor Day - 8) will be enriched for FATE-NK100 per CMC. IL-2 at 6 million IU subcutaneously (SC) every other day (EOD) for 6 doses with Dose 1 on Day 0 (no sooner than 4 hours post NK cells) and last dose no later than Day +12.

Locations

Country	Name	City	State
United States	University of Minnesota, Masonic Cancer Center	Minneapolis	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Masonic Cancer Center, University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerated dose (MTD)	Maximum FATE-NK100 dose which could be given to 3 participants such that not more than 1 participant experienced a DLT.	3 months
Secondary	Clinical activity by CR/CRp leukemia clearance	Incidence of CRp defined as leukemia clearance (=5%marrow blasts and no circulating peripheral blasts)	Day +42
Secondary	Clinical activity by CR/CRp neutrophil recovery	Incidence of CRp defined as neutrophil recovery (ANC >500 cells/microliter) but with incomplete platelet recovery	Day +42
Secondary	In vivo expansion of NK cells	Incidence of in vivo expansion (= 100 donor derived NK cells per uL blood) of NK cells	Day +14
Secondary	Treatment Related Mortality (TRM)	Incidence of treatment related mortality (TRM)	6 months
Secondary	Minimal residual disease (MRD) by bone marrow morphology	Incidence of minimal residual disease (MRD) clearance by bone marrow morphology after NK Cell infusion	up to Day 28
Secondary	Minimal residual disease (MRD) by flow cytometry	Incidence of minimal residual disease (MRD) clearance by flow cytometry after NK Cell infusion	up to Day 28
Secondary	Leukemia free survival (LFS)	Incidence of Leukemia free survival (LFS)	1 year
Secondary	Overall survival (OS)	Incidence of overall survival (OS)	1 year